Eli Lilly and Company (NYSE:LLY) Shares Acquired by Penobscot Investment Management Company Inc.

Penobscot Investment Management Company Inc. lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 9.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,380 shares of the company’s stock after buying an additional 552 shares during the quarter. Penobscot Investment Management Company Inc.’s holdings in Eli Lilly and Company were worth $3,719,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in LLY. International Assets Investment Management LLC raised its stake in shares of Eli Lilly and Company by 61,268.8% during the 4th quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock worth $42,802,530,000 after buying an additional 7,330,815 shares during the period. Sapient Capital LLC acquired a new position in shares of Eli Lilly and Company during the 4th quarter worth approximately $617,312,000. J.P. Morgan Private Wealth Advisors LLC acquired a new position in Eli Lilly and Company in the 3rd quarter valued at $435,736,000. Vanguard Group Inc. raised its stake in Eli Lilly and Company by 0.9% in the 3rd quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock valued at $37,908,273,000 after purchasing an additional 659,838 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA raised its stake in Eli Lilly and Company by 24.2% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,310,859 shares of the company’s stock valued at $1,778,362,000 after purchasing an additional 645,473 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Up 5.4 %

Shares of NYSE LLY traded up $39.51 during mid-day trading on Tuesday, reaching $776.71. 4,714,075 shares of the company’s stock were exchanged, compared to its average volume of 3,036,286. The firm has a market capitalization of $738.00 billion, a price-to-earnings ratio of 134.72, a PEG ratio of 1.60 and a beta of 0.34. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. Eli Lilly and Company has a 52-week low of $392.26 and a 52-week high of $800.78. The company’s 50-day moving average is $760.89 and its 200-day moving average is $668.00.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The business had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. During the same period in the prior year, the business posted $2.09 EPS. The company’s revenue was up 28.1% compared to the same quarter last year. Analysts expect that Eli Lilly and Company will post 12.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. JPMorgan Chase & Co. increased their price objective on Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a research note on Friday, March 15th. Cantor Fitzgerald reissued an “overweight” rating and issued a $815.00 price objective on shares of Eli Lilly and Company in a research note on Monday, April 15th. Morgan Stanley increased their price objective on Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research note on Friday, February 16th. Bank of America increased their price objective on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Finally, DZ Bank downgraded Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective for the company. in a research note on Wednesday, February 21st. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus target price of $728.05.

Insider Activity at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the firm’s stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the completion of the transaction, the insider now directly owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.